Related Experiment Video
Updated: Aug 15, 2026

Murine Heterotopic Heart Transplant Technique
Published on: July 8, 2014
Attenuated acute cardiac rejection in NOS2 -/- recipients correlates with reduced apoptosis
J Koglin1, D J Granville, T Glysing-Jensen
1Cardiovascular Biology Laboratory, Harvard School of Public Health, Boston, Mass. 02115, USA.
Background:
The mechanisms through which NOS2-mediated pathways regulate graft failure in acute cardiac rejection are ill defined. To determine whether apoptosis promoted by NOS2 may contribute, we used a heterotopic transplant model to study mouse cardiac allografts placed in recipients with targeted gene deletion of NOS2.
Methods And Results:
Using 5 different indexes of apoptosis, we showed that mouse cardiac allografts placed in NOS2 -/- recipients (n=7) had reduced apoptotic activity compared with those in NOS2 +/+ controls (n=8). There were significantly fewer TUNEL-positive nuclei per high-powered field (P<0.01), less DNA fragmentation (antinucleosome ELISA; P<0.05), lower corrected transcript levels for caspase-1 and -3 (32P reverse transcriptase-polymerase chain reaction; P<0.01), and reduced caspase-3 activity (cleavage of DEVD-pNA [P<0.001] and poly [ADP-ribose] polymerase) in grafts from NOS2 -/- recipients. This concordant reduction in apoptotic indexes paralleled the improved histological outcome of grafts transplanted into NOS2 -/- recipients (assessed as rejection scores; P=0.012). To identify pathways controlled by NOS2, we compared intragraft transcript levels of potential triggers and regulators. Whereas Fas ligand/Fas and tumor necrosis factor (TNF)-alpha/TNF receptor-1 levels were not altered by NOS2 deficiency, transcript levels for p53 were significantly lower in grafts from NOS2 -/- recipients, coinciding with a significant increase in the antiapoptotic Bcl-2/Bax balance and decrease in Bcl-Xl levels.
Conclusions:
Using NOS2 knockout mice, we demonstrated that NOS2-mediated pathways can promote acute rejection, at least in part, by inducing apoptotic cell death. When NOS2 is present, p53 might control NOS2-mediated apoptosis by stimulating Bax and repressing Bcl-2 and Bcl-Xl expression, which may activate the cell death program in the rejecting heart.
Insights
Nitric oxide synthase 2 (NOS2) promotes acute cardiac allograft rejection by inducing apoptosis. NOS2 knockout mice show reduced graft apoptosis and improved outcomes, suggesting NOS2 is a therapeutic target.
Area of Science:
- Immunology
- Molecular Biology
- Transplantation Science
Background:
- Mechanisms of graft failure in acute cardiac rejection are not fully understood.
- The role of nitric oxide synthase 2 (NOS2) in promoting apoptosis during rejection is unclear.
Purpose of the Study:
- To investigate if NOS2-mediated pathways contribute to graft failure by inducing apoptosis.
- To determine the role of NOS2 in acute cardiac allograft rejection using a knockout mouse model.
Main Methods:
- Utilized a heterotopic cardiac transplant model in mice with targeted gene deletion of NOS2 (NOS2-/-) and wild-type controls (NOS2+/+).
- Assessed apoptosis using five distinct indexes, including TUNEL staining, DNA fragmentation, caspase activity, and gene expression analysis.
- Analyzed intragraft transcript levels of apoptosis-related genes, including p53, Bcl-2, Bax, and Bcl-Xl.
Main Results:
- NOS2-/- recipients exhibited significantly reduced apoptotic activity in cardiac allografts compared to NOS2+/+ controls.
- Key apoptosis markers (TUNEL, DNA fragmentation, caspase-1/-3 levels, caspase-3 activity) were significantly lower in grafts from NOS2-/- mice.
- Improved histological outcomes (lower rejection scores) correlated with reduced apoptosis in grafts from NOS2-/- recipients.
- NOS2 deficiency led to lower p53 transcript levels and an altered Bcl-2/Bax and Bcl-Xl balance, favoring apoptosis resistance.
Conclusions:
- NOS2-mediated pathways significantly contribute to acute cardiac allograft rejection by inducing apoptotic cell death.
- In the presence of NOS2, p53 may regulate apoptosis by modulating Bax, Bcl-2, and Bcl-Xl expression, thereby activating cell death pathways in rejecting hearts.
More Related Videos
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure II: Pathophysiology

